Related Experiment Video
Updated: Nov 24, 2025

Author Spotlight: Advancements in Cell and Tissue Engineering for Tendon Repair
Published on: March 1, 2024
Anoikis resistance conferred by tenascin-C-derived peptide TNIIIA2 and its disruption by integrin inactivation
Motomichi Fujita1, Manabu Sasada2, Takuya Iyoda3
1Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.
Abstract:
Glioblastoma multiforme (GBM), the most common brain tumor in adults, has an extremely poor prognosis, which is attributed to the aggressive properties of GBM cells, such as dysregulated proliferation and disseminative migration. We recently found that peptide TNIIIA2, derived from tenascin-C (TNC), which is highly expressed in GBM, contributes to the acquisition of these aggressive properties through β1-integrin activation. In general, cancer cells often acquire an additional malignant property that confers resistance to apoptosis due to loss of adhesion to the extracellular matrix, termed anoikis resistance. Our present results show that regulation of β1-integrin activation also plays a key role in both the development and loss of anoikis resistance in GBM cells. Despite being derived from a GBM with an extremely poor prognosis, the human GBM cell line T98G was susceptible to anoikis but became anoikis resistant via treatment with peptide TNIIIA2, which is able to activate β1-integrin. The TNIIIA2-conferred anoikis resistance of T98G cells was disrupted by further addition of peptide FNIII14, which has the ability to inactivate β1-integrin. Moreover, anchorage-independent survival of GBM cells in suspension culture was abrogated by peptide FNIII14, but not by RGD and CS-1 peptides, which are antagonistic for integrins α5β1, αvβ3, and α4β1. These results suggest that GBM cells develop anoikis resistance through activation of β1-integrin by TNC-derived peptide TNIIIA2, which is abundantly released into the tumor microenvironment of GBM. Inactivation of β1-integrin may provide a promising strategy to overcome the apoptosis resistance of cancer cells, including GBM.
Insights
Tenascin-C peptide TNIIIA2 activates beta1-integrin, conferring anoikis resistance in glioblastoma multiforme (GBM) cells. Inactivating beta1-integrin with peptide FNIII14 overcomes this resistance, offering a potential therapeutic strategy for GBM.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis, characterized by uncontrolled cell growth and migration.
- Cancer cells often develop resistance to apoptosis (anoikis) when detached from the extracellular matrix, contributing to tumor progression.
- Tenascin-C (TNC), highly expressed in GBM, and its derived peptide TNIIIA2, are implicated in GBM aggressiveness via beta1-integrin activation.
Purpose of the Study:
- To investigate the role of beta1-integrin activation in anoikis resistance in GBM cells.
- To determine if TNC-derived peptide TNIIIA2 influences anoikis resistance in GBM.
- To explore the potential of targeting beta1-integrin for overcoming GBM apoptosis resistance.
Main Methods:
- Utilized the human GBM cell line T98G, which is initially susceptible to anoikis.
- Treated T98G cells with peptide TNIIIA2 to induce anoikis resistance and peptide FNIII14 to inactivate beta1-integrin.
- Assessed anchorage-independent survival in suspension culture using various peptides, including TNIIIA2, FNIII14, RGD, and CS-1.
Main Results:
- Peptide TNIIIA2 treatment rendered anoikis-susceptible T98G cells resistant to anoikis by activating beta1-integrin.
- The TNIIIA2-induced anoikis resistance was reversed by the addition of peptide FNIII14, which inactivates beta1-integrin.
- Peptide FNIII14 abrogated anchorage-independent survival of GBM cells, while RGD and CS-1 peptides did not.
Conclusions:
- GBM cells acquire anoikis resistance through beta1-integrin activation, mediated by TNC-derived peptide TNIIIA2 present in the tumor microenvironment.
- Inactivation of beta1-integrin presents a promising therapeutic strategy to combat apoptosis resistance in GBM and potentially other cancers.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Tension Response at Adherens Junctions
α-Catenin as a Mechanosensory Protein
The α-catenin of adherens junctions is an allosteric protein with three VH (vinculin...
Cancer Cell Migration through Invadopodia
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

